| Professional Services Industry | Industrials Sector | Hanne Andersen-Elyard CEO | OTC PINK Exchange | 09065J101 CUSIP |
| US Country | 278 Employees | 7 Oct 2024 Last Dividend | 30 Oct 1997 Last Split | - IPO Date |
Bioqual, Inc. is a distinguished provider of in-vivo and in-vitro pre-clinical research services, catering to the needs of both commercial and government entities across the United States. Since its establishment in 1981, the company has been headquartered in Rockville, Maryland, and has developed a reputation for its expertise in a broad range of infectious diseases and medical conditions, including COVID-19, AIDS, influenza, RSV infection, and various flavivirus infections such as zika and dengue. Bioqual, Inc. plays a critical role in advancing medical research and development efforts, particularly in the realms of infectious diseases, hepatitis, malaria, cancer, and more, employing state-of-the-art methodologies and technology.
Bioqual, Inc. offers a comprehensive suite of research services to support the development and testing of vaccines, therapeutics, and diagnostics. These include:
In addition to these specialized research services, Bioqual, Inc. also offers services related to the use and management of animal research models, further supporting the scientific community in their pursuit of breakthrough discoveries in medicine and biology.